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The p53 tumour suppressor plays a pivotal role in the prevention of oncogenic transformation. Cancers frequently evade the
potent antitumour surveillance mechanisms of p53 through mutation of the TP53 gene, with approximately 50% of all human
malignancies expressing dysfunctional, mutated p53 proteins. Interestingly, genetic lesions in the TP53 gene are only observed
in 10% of Ewing Sarcomas, with the majority of these sarcomas expressing a functional wild-type p53. In addition, the p53
downstream signaling pathways and DNA-damage cell cycle checkpoints remain functionally intact in these sarcomas. This paper
summarizes recent insights into the functional capabilities and regulation of p53 in Ewing Sarcoma, with a particular focus on the
cross-talk between p53 and the EWS-FLI1 gene rearrangement frequently associated with this disease. The development of several
activators of p53 is discussed, with recent evidence demonstrating the potential of small molecule p53 activators as a promising
systemic therapeutic approach for the treatment of Ewing Sarcomas with wild-type p53.
1.Introduction
The p53 protein, known as the “guardian of the genome”
[1] and voted Science magazine’s “Molecule of the Year”
in 1993, plays a pivotal role in the cellular defense against
transformation of cells in the presence of oncogenic or
genotoxic stress [2]. This is achieved through the ability
of the p53 transcription factor to drive the expression of
downstream target genes to evoke cellular responses such
as cell cycle arrest, apoptosis, DNA damage repair, and
senescence [3]. The development of a malignant neoplasm
generally requires attenuation of these p53 responses, and
this can occur via mutation of the p53 protein. TP53
is the most frequently altered gene in cancer, with p53
mutations observed in approximately half of all tumours [4].
In contrast, TP53 mutations are infrequent in the Ewing
S a r c o m aF a m i l yo fT u m o u r s( E S F T s )w i t ht h em a j o r i t yo f
these sarcomas expressing a functional wild-type p53 [5–14].
Such features are rarely seen in cancers and are suggestive
that ESFTs will be sensitive to p53-based targeted therapeutic
strategies.
2. Genomic Integrityof TP53 Is Preserved in
Ewing Sarcomas
Ewing Sarcomas arise in the bones of children and young
adolescents and are the most lethal of all bone tumours
[15, 16]. These sarcomas are infrequent neoplasms with
international incidence rates in the pediatric population
averaging less than two cases per million children. Such low
incidence rates have limited the detection of TP53 mutations
to relatively small cohorts from independent clinical centres,
with these studies reporting TP53 mutation frequencies
ranging from 4% to 20%. A meta-analysis of all primary or
metastatic ESFTs involving TP53 point mutations conﬁrmed
through direct sequencing reveals that TP53 mutations are
observed in approximately 10% of cases (Table 1).
A similar analysis of the available literature suggests that
the majority of other sarcoma types are also associated with
low frequencies of TP53 mutations, ranging from approxi-
mately 6% in well-diﬀerentiated/dediﬀerentiated liposarco-
mas to 23% in osteosarcomas (Table 2). Although malignant
ﬁbrous histiocytomas are listed, they are a discredited2 Sarcoma
Table 1: TP53 Mutations in Ewings Sarcoma conﬁrmed by DNA sequencing.
Sarcoma type Study Method Exons
sequenced
Mutation
frequency TP53 mutation
Ewing Sarcoma
Kovar et al., 1993 [5] PCR-SSCP
Sequencing 4–8 2/37 C277Y, R273C
Komuro et al., 1993 [6] PCR-SSCP
Sequencing 5–9 2/14 152(FS), G154V
Hamelin et al., 1994 [7] PCR-DGGE
Sequencing 5–8 2/12 R175H,R248W
Pati˜ no-Garc´ ıa and
Sierrases´ umaga, 1997 [8]
PCR-DDGE
Sequencing 5–8 1/5 R273H
Radig et al., 1998 [9]
IHC
PCR-SSCP
Sequencing
4–8 1/24 Not Speciﬁed
Tsuchiya et al., 2000 [10] PCR-SCCP
Sequencing 5–9 1/24 G154V
L´ opez-Guerrero et al.,
2001 [11] Sequencing 5–8 3/19 C135F, A138D, P151R
Park et al., 2001 [13] PCR-SSCP
Sequencing 4–9 3/35 K132M, C135S, Q287V
Huang et al., 2005 [12]
IHC
p53
GeneChip
Sequencing
—8 / 6 0
W146(STOP), M160L
N239A, G244I, R248Q
R273F, A276S, R342P
Schaefer et al., 2008 [14] Sequencing 5–8 2/17 C141Y, R248W
Total TP53 mutations in Ewing Sarcoma 25/247 (10.1%)
DDGE: Denaturing Gradient Gel Electrophoresis; IHC: Immunohistochemistry; PCR-SSCP: Polymerase Chain Reaction Single-Strand Conformational
Polymorphism; FS: Frameshift; Mutations in bold indicate p53 “hotspot mutations.”
entity and will soon be removed from the World Health
Organisation (WHO) sarcoma atlas [17]. Collectively, Ewing
Sarcoma was associated with the lowest frequencies of TP53
mutation across all sarcoma types.
TheInternationalAgencyforResearchonCancer(IARC)
has recently released recommendations for the detection of
TP53 mutations, and advise direct sequencing of exons 4
to 10 of the TP53 gene [46]. Studies listed in Tables 1 and
2 rarely fulﬁlled these recommendations. Furthermore, the
reported frequencies of TP53 mutations may be marginally
underestimated as the majority of these studies sequenced
TP53 in patients where an initial screen detected overex-
pressed p53 protein by immunohistochemistry, rather than
performing an unbiased sequencing of all cases. Although
mutant p53 is typically stabilized in cancer cells, and
overexpression of p53 protein is predictive of TP53 mutation
[47], this indirect approach cannot detect heterozygous
truncatingmutationsofTP53[46].Nevertheless,frequencies
of TP53 mutation reported by the studies in Tables 1 and 2
are consistent with publicly available sequencing data from
theIARCTP53databaseinwhichTP53pointmutationswere
observed in 373 out of 2145 (17.4%) tumours from bone or
soft tissue origins [46].
The integrity of the p53 pathway in Ewing Sarcomas is
further supported by studies suggesting that gross chromo-
somal alterations involving the TP53 locus on chromosome
17p are relatively infrequent in ESFT samples [48]. This is
in contrast to other bone malignancies, such as osteosarco-
mas, where chromosome alterations of the TP53 gene are
frequently observed [24, 44, 49, 50].
3. GeneticAlterationsin
Regulators of the p53 Pathway
Typically, cancers that retain wild-type p53 have been shown
to indirectly suppress the p53 regulatory and signaling
pathways. One of the most common oncogenic defects
observed involves ampliﬁcation or overexpression of MDM2
[51]. The stability and activity of p53 are constitutively
regulated by MDM2 using an auto-regulatory feedback loop
which in normal cells prevents inappropriate activation of
p53 [52]. MDM2 is an E3 ubiquitin ligase that antagonizes
the tumour suppressor function of p53 by silencing the
ability of p53 to transactivate target genes or promoting
its degradation or nuclear exportation [53, 54]. However,
MDM2ampliﬁcationisarareeventinEwingSarcomasandis
only observed in approximately 2% of ESFT cases (Table 3).
In contrast, virtually all well-diﬀerentiated and dediﬀeren-
tiated liposarcomas contain complex marker chromosomes
with multiple copies of the MDM2 locus [55].
Cancerscanalsoattenuatep53functionthroughdeletion
of CDKN2A, the gene encoding p14ARF [48]. The p14ARF
tumour suppressor is a positive regulator of p53 in response
to speciﬁc stimuli such as oncogenic stress. The stability of
p53 is enhanced by p14ARF through its ability to sequester
MDM2, thus releasing p53 to activate downstream pathwaysSarcoma 3
Table 2: TP53 Mutations in sarcomas other than ESFTs conﬁrmed by DNA sequencing.
Sarcoma type Study Method Exons
sequenced
Mutation
frequency TP53 mutation
Liposarcoma
Well-diﬀerentiated/de-
diﬀerentiated
liposarcoma
(WD/DDLPS)
Pilotti et al., 1997 [18]
IHC
PCR-SSCP
Sequencing
5–9 4/13 H179Y, R213(STOP)
R282W,G g> Gc (SS)
Dei Tos et al., 1997
[19]
IHC
PCR-SSCP
Sequencing
5–8 1/14 S127F
Schneider-Stock et al.,
1998 [20]
PCR-SSCP
Sequencing 4–8 0/8 —
Schneider-Stock et al.,
1999 [21]
IHC
PCR-SSCP
Sequencing
5–8 0/13 —
Barretina et al., 2010
[22]
Sequencing,
mass
spectrometry-
based
genotyping
—0 / 5 0 —
Total TP53
mutations 5/98 (5.1%)
Myxoid/Round cell
liposarcoma
Pilotti et al., 1997 [18]
IHC
PCR-SSCP
Sequencing
5–9 1/6 Del nts 1506-1507 (STOP)
Schneider-Stock et al.,
1998 [20]
PCR-SSCP
Sequencing 4–8 1/12 P128S
Schneider-Stock et al.,
1999 [21]
IHC
PCR-SSCP
Sequencing
5–8 3/19 H214L, P250T, G245S
Oda et al., 2005 [23]
IHC
PCR-SSCP
Sequencing
5–9 5/77 Q167(STOP), H214Y
V225A, C238Y, C242Y
Barretina et al., 2010
[22]
Sequencing, mass
spectrometry-
based
genotyping
—0 / 2 1 —
Total TP53
Mutations 10/135 (7.4%)
Pleomorphic
liposarcoma
Schneider-Stock et al.,
1998 [20]
PCR-SSCP
Sequencing 4–8 3/6 R248Q, E271(STOP)
R273C
Schneider-Stock et al.,
1999 [21]
IHC
PCR-SSCP
Sequencing
5–8 2/9 R248Q, R273C
Barretina et al., 2010
[22]
Mass
spectrometry-
based
genotyping
—4 / 2 4 C135F, T155I
C > TT (SS), C > CT (SS)
Total TP53
mutations 9/39 (23.1%)
Undeﬁned
liposarcomas
Toguchida et al., 1992
[24]
PCR-SSCP
Sequencing 2–11 1/4 AGgt > AGtt (SS)
Leach et al., 1993 [38] IHC
Sequencing 5–8 3/13 Q144(STOP), N239S
GGT > GAT (SS)
Latres et al., 1994 [25] PCR-SSCP
Sequencing 2–9 5/25 H168R, H193Y, M246V
R248W, 344(STOP)
Castresana et al., 1995
[26]
PCR-SSCP
Sequencing 5–8 1/4 V216A4 Sarcoma
Table 2: Continued.
Sarcoma type Study Method Exons
sequenced
Mutation
frequency TP53 mutation
Nawa et al., 1999 [27] PCR-SSCP
Sequencing 5–8 1/9 T253A
Das et al., 2007 [28] IHC
Sequencing 2–11 1/3 377(FS)
Total TP53
mutations 12/58 (20.7%)
Total TP53 mutations in liposarcomas 36/330 (10.9%)
Rhabdomyosarcoma
Felix et al., 1992 [29] PCR-SSCP
Sequencing 4–8 1/6 R213P
Toguchida et al., 1992
[24]
PCR-SSCP
Sequencing 2–11 0/4 —
Latres et al., 1994 [25] PCR-SSCP
Sequencing 2–9 0/2 —
Castresana et al., 1995
[26]
PCR-SSCP
Sequencing 5–8 1/1 V218L
Kusafuka et al., 1997
[30]
PCR-SSCP
Sequencing 5–8 1/10 R273H
Nawa et al., 1999 [27] PCR-SSCP
Sequencing 5–8 0/2 —
Taylor et al., 2000 [31] PCR-SSCP
Sequencing 5–9 1/20 Del nt 1004-1017
Takahashi et al., 2004
[32]
PCR-SSCP
Sequencing 5–9 9/45
E204G, R209T, P223R
M243T, G245C, N247D,
R249G, C291Q, P295H
Das et al., 2007 [28] IHC
Sequencing 2–11 1/4 D393N
Total TP53 mutations in rhabdomyosarcomas 14/94 (14.9%)
Synovial Sarcoma
Toguchida et al., 1992
[24]
PCR-SSCP
Sequencing 2–11 0/5 —
Latres et al., 1994 [25] PCR-SSCP
Sequencing 2–9 0/8 —
Schneider-Stock et al.,
1997 [33]
IHC
PCR-SSCP
Sequencing
5–8 0/2 —
Dei Tos et al., 1999
[34]
PCR-SSCP
Sequencing — 4/20 Not Speciﬁed
Nawa et al., 1999 [27] PCR-SSCP
Sequencing 5–8 1/7 L194F
Schneider-Stock et al.,
1999 [35]
IHC
PCR-SSCP
Sequencing
5–8 2/19 P128L, R248W
Oda et al., 2000 [36]
IHC
PCR-SSCP
Sequencing
5–9 9/49
C141Y, A159T,V173M
I195F, R196Q, G199R
R213(STOP), N235D
C238Y
Das et al., 2007 [28] IHC
Sequencing 2–11 5/7 9(STOP), A63P, S96C,
P250T, P250T
Barretina et al., 2010
[22]
Sequencing, mass
spectrometry-
based
genotyping
—0 / 2 3 —
Total TP53 mutations in Synovial Sarcomas 21/140 (15.0%)Sarcoma 5
Table 2: Continued.
Sarcoma type Study Method Exons
sequenced
Mutation
frequency TP53 mutation
Malignant Fibrous
Histiocytoma
Toguchida et al., 1992
[24]
PCR-SSCP
Sequencing 2–11 2/13 R196(STOP), R273H
Andreassen et al.,
1993 [37]
CDGE
Sequencing 5,7,8 3/12 V143M, Y163C, G244D
Leach et al., 1993 [38] IHC
Sequencing 5–8 1/11 R158H
Latres et al., 1994[25] PCR-SSCP
Sequencing 2–9 0/9 —
Castresana et al., 1995
[26]
PCR-SSCP
Sequencing 5–8 3/12 Not Speciﬁed
Schneider-Stock et al.,
1997 [33]
IHC
PCR-SSCP
Sequencing
5–8 2/15 Y220C, C277(STOP)
Nawa et al., 1999[27] PCR-SSCP
Sequencing 5–8 5/15
Y126F, R175H
R213(STOP), S241T
R248Q
Das et al., 2007 [28] IHC
Sequencing 2–11 2/11 P77Q, 213(FS)
Total TP53 mutations in malignant ﬁbrous histiocytoma 18/98 (18.4%)
Leiomyosarcoma
Andreassen et al.,
1993 [37]
CDGE
Sequencing 5,7,8 2/6 K132M, R248W
Latres et al., 1994[25] PCR-SSCP
Sequencing 2–9 5/13
Y163C, Y163C, H214R,
G266E,
ATgg > ATag (SS Intron 5)
Patterson et al., 1994
[39]
PCR-SSCP
Sequencing 4–9 6/29 P151H, P152L, R158H
V216M, C238F, V272M
Castresana et al., 1995
[26]
PCR-SSCP
Sequencing 5–8 1/1 Not Speciﬁed
Miller et al., 1996 [40] PCR-SSCP
Sequencing 2–11 1/8 Q165(STOP)
Hall et al., 1997 [41]
IHC
PCR-SSCP
Sequencing
5–8 3/21 K163E, T211I
A nt Del codon 246
Schneider-Stock et al.,
1997 [33]
IHC
PCR-SSCP
Sequencing
5–8 0/7 —
Nawa et al., 1999[27] PCR-SSCP
Sequencing 5–8 0/3 —
Zhai et al., 1999 [42] IHC
Sequencing 5–8 9/21
V173M, Y205C, S215R,
R248Q, R249W, R273H,
A276D, E285D, S303I
Miyajima et al., 2001
[43]
IHC
PCR-SSCP
Sequencing
5–9 8/13
A161T, D184N, T220C
T220C, C238S, C238C
R273H, G279V
Das et al., 2007 [28] IHC
Sequencing 2–11 0/5 —
Barretina et al., 2010
[22]
Sequencing, mass
spectrometry-
based
genotyping
—0 / 2 7 —
Total TP53 mutations in leiomyosarcomas 35/154 (22.7%)6 Sarcoma
Table 2: Continued.
Sarcoma type Study Method Exons
sequenced
Mutation
frequency TP53 mutation
Osteosarcoma
Toguchida et al., 1992
[24]
PCR-SSCP
Sequencing 2–11 14/76
46 (STOP),
112 (STOP), R175H
H193Q, E221(STOP)
227(STOP), S241Y
G244V, P250L, D259V
R273H, D281H, D281N
aaTG > ggTCG (SS)
Andreassen et al.,
1993 [37]
CDGE
Sequencing 5, 7, 8 2/11 D281E, E286K
Castresana et al., 1995
[26]
PCR-SSCP
Sequencing 5–8 2/7 169(STOP), D281Y
Miller et al., 1996 [40] PCR-SSCP
Sequencing 2–11 13/42
H179Y, E224D, 239(FS),
G245D, R248W, R248,
248(FS), R273H
R273H, A276P
R282Q, R282Q
R282H
Pati˜ no-Garc´ ıa and
Sierrases´ umaga, 1997
[8]
PCR-DDGE
Sequencing 5–8 6/37
R175H, R196(STOP)
P250F, N268S, R273H
R2735
Gokgoz et al., 2001
[44]
PCR-SCCP
Sequencing 4–10 60/272
agTCC > aaTCC (SS)
L43(STOP), L43(STOP),
P47L, 73(FS), 73(FS),
83(FS), 83(FS)
In-Frame Ins (GGT)
Codon
107/108
ACGgt/ACGtt(SS),
agTAC/aaTAC (SS),
V172D, R175H
ATGgt/ATGat(SS),
R181P, R196(STOP)
V197G,
Del codon 202–206,
E204(STOP), Y205C
R213(STOP), Y220C
Y220C, E221(STOP)
31bp Del (FS) Intron 6 to
Exon 7
229(FS), M237I, M237I,
M237I, C238GC238G,
C238G
241(FS), C242Y, C242Y,
G245S, G245S
R248W, R248Q, R248Q,
R248Q, R248Q, P250L,
T256S
15bp In-frame Del (codon
265)
R273H, R273H, R273H,
R280H, D281H, D281H
D281N, D281N
E285K,
Del codon 296–303
298(FS)
GAGgt/GAGct (SS)
R337C, R342(STOP)
E343(STOP)Sarcoma 7
Table 2: Continued.
Sarcoma type Study Method Exons
sequenced
Mutation
frequency TP53 mutation
Overholtzer et al.,
2003 [45]
PCR-SCCP
PCR-LDR 5–8 12/32
V173G, V173M, R175H,
Del codon 175,
Y220C, E224D, V272M,
R273H, R273C, D281H
FS (Exon 6),
FS (Del 17nt) Exon 5
Total TP53 mutations in osteosarcomas 109/477 (22.9%)
CDGE: Constant Denaturant Gel Electrophoresis; DDGE: Denaturing Gradient Gel Electrophoresis; IHC: Immunohistochemistry; PCR-SSCP: Polymerase
Chain Reaction Single-Strand Conformational Polymorphism; PCR-LDR: Polymerase Chain Reaction Ligase-Detection Reaction; FS: Frame shift; Del:
Deletion; Ins: Insertion; SS: Splice Site. Mutations in bold indicate p53 “hotspot mutations”. Recurrences with TP53 mutations have been omitted in studies
that reported both the primary tumour and recurrence with the same mutation.
of growth suppression or apoptosis [56, 57]. A summary
of the available literature related to CDKN2A chromosomal
alterations in ESFT cases revealed that either homozygous
or hemizygous deletion of the CDKN2A locus are also
relatively infrequent events, occurring in less than 20% of
all cases (Table 3). CDKN2A alterations and TP53 mutations
are mutually exclusive events in the majority of ESFT cases,
suggesting that either genetic insult is suﬃcient to inactivate
the p53 pathway in these cancers [11, 48].
MDM4 is another key negative regulator of the p53
pathway [61–63]. This oncoprotein is closely related to
MDM2 with signiﬁcant homology between their DNA
binding domains; however, MDM4 has a more speciﬁc role
in the negative regulation of p53 transcriptional activity.
Ampliﬁcation of the MDM4 gene has also been reported in
several tumour types, with MDM4 ampliﬁcation observed
in 65% of retinoblastomas [64]. MDM2 and MDM4
ampliﬁcation are rarely observed within the same tumour,
suggesting that either event is suﬃcient to inactivate the p53
pathway. MDM4 ampliﬁcation is a possible mechanism for
functionalinactivationofthep53pathwayinEwingSarcoma
given the infrequent occurrences of MDM2 ampliﬁcation,
CDKN2A deletion, or TP53 mutation in these cancers.
Unfortunately, previous cytogenetic studies are restricted
to investigating allelic imbalance of the TP53, MDM2, and
CDKN2A loci in ESFT patient material, hence the frequency
of MDM4 ampliﬁcations in Ewing Sarcoma is currently
unknown.
The small proportion of ESFT cases with either MDM2
ampliﬁcation or p14ARF deletion cannot collectively account
for the ability of Ewing Sarcomas to develop in a cellular
context with wild-type p53. Further investigations of Ewing
Sarcoma are warranted to conclusively determine if the
mechanisms that attenuate the p53 response during sarco-
magenesis occur at the genetic or posttranslational level. The
presence of an EWS-ETS translocation event is a universal
feature of Ewing Sarcoma and represents another possible
genetic alteration responsible for the regulation of p53 in
ESFT. Recent insights into the functional characterization
of the resulting oncogenic gene product suggest a potential
role of this ubiquitous translocation event in silencing p53
activity in ESFTs (see later discussion).
4.The p53 SignalingPathways
AreFunctionallyIntactinEwingSarcoma
Abrogation of the p53 pathway through TP53 mutation
is typically associated with enhanced tumour invasive and
metastatic capabilities, and poorer patient survival rates [46,
65]. Ewing Sarcoma is an aggressive malignancy with the
lowest patient survival rates of all primary musculoskeletal
tumours, traits rarely possessed by cancers that retain wild-
type p53. Despite observations that TP53 alterations and
MDM2 ampliﬁcations are infrequent events in primary
Ewing Sarcomas, it has been speculated that the downstream
signaling pathways of p53 may be inactive in these sarcomas.
In order to test the functional intactness of these p53
signaling pathways in Ewing Sarcoma, Heinrich Kovar and
colleagues investigated the response of several ESFT cell
lines with varying p53 status to ectopic p53 expression
[66]. A prolonged apoptotic or growth arrest phenotype
was observed upon ectopic expression of wild-type p53 in
the cell lines. The sensitivity of Ewing Sarcoma cell lines
to X-irradiation was also dependent on the expression of
an endogenous wild-type p53. These ﬁndings conﬁrm the
intactness of the p53 signaling pathways in Ewing Sarcoma.
The frequent normal functioning of the p53 signaling
pathway in ESFTs is also demonstrated by the observation
that almost all Ewing Sarcoma cell lines have acquired either
TP53 mutations or CDKN2A deletions, suggesting selective
pressure for these genetic alterations to permit in vitro
growth [67]. Similar observations have been made in the
clinic, with p53 mutation and CDKN2A deletion deﬁning
a lethal subset of ESFTs associated with poor response to
chemotherapy [12]. In conclusion, the in vitro and in vivo
evidence suggests the p53 signaling pathways are intact in a
signiﬁcant proportion of Ewing Sarcomas.
5. The PrognosticSigniﬁcanceof
TP53 Alterations
ESFT patients with point mutation of TP53 are associated
with a poor prognosis [12, 68, 69]. Logically, one would
expect a genetic event that confers a growth advantage to be
highly represented across a tumour type through selective
pressure. This is not the case in Ewing Sarcoma, as TP538 Sarcoma
Table 3: MDM2 ampliﬁcation or CDKN2A deletion in Ewing Sarcomas.
Study MDM2 ampliﬁcation Study CDKN2A deletion
Kovar et al., 1993 [5] 0/17 Kovar et al., 1997 [5]7 / 2 7 #
Ladanyi et al., 1995 [58] 3/30 Wei et al., 2000 [59]7 / 3 9 #
Tsuchiya et al., 2000 [10]0 / 2 4 L ´ opez-Guerrero et al., 2001 [11]4 / 1 9 #
Park et al., 2001 [13] 0/35 Brownhill et al., 2007 [60]6 / 4 2 ∗
L´ opez-Guerrero et al., 2001 [11]0 / 1 9 L ´ opez-Guerrero et al., 2010 [48] 34/169∗
Total MDM Ampliﬁcations 3/125 (2.4%) Total CDKN2A Deletions 58/296 (19.6%)
#Homozygous deletion of CDKN2A
∗Includes both homozygous and hemizygous deletions of CDKN2A.
mutations rarely occur, yet deﬁne a high-risk population of
patients.
Huang and colleagues have provided the most com-
pelling evidence thus far for TP53 mutation as an inde-
pendent prognostic marker using a combined immunohis-
tochemistry, Genechip and sequencing approach to detect
TP53 mutations in 60 ESFTs [12]. TP53 mutations were
identiﬁedin8ofthese60cases(13.3%),andalleightpatients
expressing mutant p53 ESFTs died within 21 months of
diagnosis with a mean survival of 11 months, as compared
to a mean survival of 99 months for patients with wild-type
p53 ESFTs. Multivariate analysis identiﬁed TP53 mutation
as the strongest independent prognostic factor [12]. This
is the largest prognostic study to date that involves DNA
sequencing of TP53 in ESFT patient material.
The prognostic involvement of p53 mutation in Ewing
Sarcoma was recently challenged by ﬁndings from a retro-
spective study involving 308 ESFT cases collected from
1971 to 2007 [48]. Although overexpression of p53 protein
was detected in 25% of these cases, this study restricted
the classiﬁcation of “p53 mutation” to these cases which
did not express p21Waf1/Cip1, the strongest canonical p53
target. Subsequently, 15% of ESFT cases where deemed
to express mutant p53 upon application of these criteria.
This study showed that “mutant p53” expression was more
frequent in disseminated disease than in primary localized
tumors, indicating a role in the progression and metastasis of
Ewing Sarcoma. However, there was no association between
“mutant p53” expression and patient survival. The conclu-
sions from this study are limited by the absence of actual
TP53 sequencing of ESFT samples to conﬁrm the presence
of TP53 mutations. These observations need to be attested
by further investigation into the prognostic value of TP53
mutations using unbiased direct sequencing approaches.
Gross chromosome rearrangements involving TP53 have
been recently reported to inﬂuence the prognosis of Ewing
Sarcoma [48, 70]. Alteration of 17p (the chromosomal arm
containing the TP53 locus) was observed in 16.7% of ESFT
samples and was associated with signiﬁcantly poorer survival
rates [70]. Lopez-Guerrero and colleagues recently showed
that alteration the TP53 locus alone was a prognostic marker
for poor patient outcome [48]. Gross alteration of TP53 gene
was detected in 32 of 191 (17%) ESFT cases. Interestingly,
the strongest prognostic information from these studies was
observed upon loss of heterozygosity (LOH) of 16q, which
occurred in 20.8% of cases and was the most signiﬁcant
indicator of poor outcome [70]. A recent study that used a
combined comparative genomic hybridization (CGH) and
expression microarray analysis identiﬁed the ANKRD11
locus at 16q24.3 as one of the most frequently deleted
and down-regulated genes in Ewing Sarcoma [71]. It is
noteworthy that ANKRD11 was recently reported as a p53
coactivator [72], suggesting that the loss of p53 activators
may contribute towards the ability of Ewing Sarcomas to
develop and progress in the presence of a wild-type p53.
Studies to date are consistent with the presence of
TP53 point mutations in deﬁning a high-risk population of
ESFT patients. However, more detailed studies are warranted
to conclusively evaluate the prognostic potential of TP53
point mutation. Collectively, these ﬁndings indicate that the
prognostic potential of mutant p53 will be fully realized
through the application of deﬁnitive approaches to detect
TP53 mutations.
6. Oncogenic EWS-ETS Translocations
ESFTs are cytogenetically diagnosed through speciﬁc genetic
rearrangement involving the EWS gene (oﬃcial symbol
EWSR1) and a member of the ETS transcription factor gene
family. This chimeric fusion protein is present in over 90% of
ESFTs[73,74]andiswidelyconsideredtobecausativeofthis
malignancy. The EWS-FLI1 translocation, t(11;22)(q24;12),
is a chromosomal aberration speciﬁc to ESFTs and accounts
for 85% of translocation events in Ewing Sarcoma. This
reciprocal translocation generates fusion of the 5  segment
of EWS on chromosome 22 with the 3  segment of FLI-1 on
chromosome11.AntisenseDNAstudieshaveconﬁrmedthat
continuous EWS-FLI1 expression is required for the in vitro
proliferation and in vivo tumorigenic capacity of Ewing Sar-
coma cells [75–78]. The second most common EWS translo-
cation described involves an in-frame fusion of the EWS and
ERG genes as a result of the t(21;22)(q22;q12) translocation,
accounting for 5% of translocations in Ewing Sarcoma [74].
7. Suppression of p53 Activityby EWS-FLI1
Attenuation of the p53 tumour surveillance mechanisms
during the development and progression of Ewing Sarcomas
may be explained through the ability of the EWS-FLI1
oncoprotein to silence p53 activity. Two independent studies
have shown that silencing of EWS-FLI1 expression in Ewing
Sarcoma cell lines increases p53 activity [79, 80], suggestingSarcoma 9
that the EWS-FLI1 fusion protein plays a role in the consti-
tutive silencing of p53 tumour suppressor activity. It appears
that EWS-FLI1 can achieve this through either an indirect
mechanism, involving the Notch signaling pathway [79], or
through the formation of a protein complex involving EWS-
FLI1 and p53 [80]. This study suggests that EWS-FLI1 atten-
uatesp53activitythroughphysicallysequestrationfacilitated
by the EWS region of the fusion protein [80]. However,
it is unclear whether interaction between p53 and EWS-
FLI1 occurs directly or is mediated through other oncogenic
binding partners. It is of great interest that the amino region
of EWS enables the recruitment of p53 to EWS-FLI1, as this
p53-binding region is present in almost all Ewing Sarcoma
genetranslocationeventsandnumerousothertranslocation-
based cancers (Table 4). Such observations suggest that these
malignancies share a common mechanism involving EWS
that may potentially involve the functional inactivation of
p53.
The ability of EWS-FLI1 to suppress p53 activity in
Ewing Sarcoma is reminiscent of the functional role of
the oncogenic translocation product in synovial sarcomas.
The presence of the SS18-SSX fusion protein as a result of
the t(X:18)(p11.2;q11.2) translocation is a universal feature
of synovial sarcoma [94]. These sarcomas abrogate p53
protein levels through its enhanced proteasomal degradation
facilitated by SS18-SSX [95]. Reminiscent of Ewing Sar-
coma, TP53 mutations are rare events in synovial sarcomas
(Table 1), suggesting that these cancers rely on the ability of
the SS18-SSX fusion protein to abrogate the p53 response,
facilitating oncogenic transformation in the presence of a
functional, wild-type p53.
8. EWS-FLI1 Expression Stimulates the p53
Pathway in Normal Cells, Fibroblasts,or
Nonmesenchymal Cells
The development of an animal model to investigate the
oncogenic properties of EWS-FLI1 has been limited by the
toxic eﬀects associated with the expression of this potent
f u s i o np r o t e i ni np r i m a r yc e l l s[ 96]. Due to the absence of
an adequate transgenic animal model for Ewing Sarcoma,
experimental approaches have been restricted to forced
expression of EWS-FLI1 in various cell lines. Introduction
of EWS-FLI1 into primary human ﬁbroblasts resulted in
a growth arrest through stimulation of the p53 pathway
[96]. Subsequent speciﬁc inhibition of p53 activity in these
ﬁbroblasts rescued the growth arrest phenotype, allowing
EWS-FLI1 to promote anchorage-independent growth of
theseﬁbroblasts.Similareﬀectshavebeenobservedinmouse
embryonic ﬁbroblasts (MEFs) in which expression of EWS-
FLI1 induced the p53-dependent growth arrest or apoptosis
[97]. This apoptotic or growth arrest response was consid-
ered to be p53-dependent, as MEFs null for p53, p19ARF,o r
p16 were unaﬀe c t e di nr e s p o n s et oE W S - F L I 1e x p r e s s i o n .
Normal cells retaliate this aberrant oncogene expression
by mounting a p53-based defense mechanism resulting in
cellular apoptosis or senescence [98, 99]. Consideration of
the responses elicited by EWS-FLI1 in normal cells therefore
suggests this fusion protein in functioning as a potent
oncogene and is reminiscent of the responses associated with
elevated levels of the MYC or RAS oncogenes.
The cellular response to ectopically expressed EWS-FLI1
variesinprimarycellsofdiﬀerentorigin.EwingSarcomasare
derived from mesenchymal progenitor cells (MPCs) [100],
and forced expression of EWS-FLI1 in MPCs was shown
to be stably maintained without growth arrest or apoptosis
whilst inducing an gene expression proﬁle similar to that of a
Ewing Sarcoma, all in the presence of a functional, wild-type
p53 [101–103]. Such ﬁndings raise questions surrounding
the ability of primary MPCs to tolerate forced EWS-FLI1
expression without engaging a p53-dependent response to
the oncogenic stress. Nevertheless, the mechanisms used by
MPCs to abide the expression of EWS-FLI1 in the presence
ofwild-typep53,whilstsuchexpressioninotherprimarycell
lines triggers a p53 response, remain largely unknown.
Attempts have been made to investigate the function
of EWS-FLI1 in a transgenic mouse model. While the
conditional expression of EWS-FLI1 in mouse MPCs did not
induce the formation of Ewing Sarcomas, this expression of
EWS-FLI1 in mice was able to inﬂuence sarcoma develop-
ment in the absence of p53 [104]. Conditional TP53 deletion
inmouseMPCsledtothedevelopmentosteosarcomaswitha
median tumour onset time of 50 weeks from birth. However,
when EWS-FLI1 was conditionally expressed in these p53-
null MPCs, an accelerated tumour growth from a median
time of 50 to 21 weeks was observed, with the histological
phenotype of these malignancies shifting towards a more
poorly diﬀerentiated sarcoma [104]. These data provide in
vivo evidence to further support the cross-talk between p53
and EWS-FLI1 which is essential in primary MPCs for the
development of Ewing Sarcomas.
9.IGF1Randp53SignalingPathways
The activity of insulin-like growth factor 1 receptor (IGF1R)
is essential for tumour development and progression
through the signaling of antiapoptotic and prosurvival
pathways [105–107]. IGF1R is also often overexpressed at
the cell surface of malignant cells and thus has emerged as
an attractive therapeutic target in cancer. A role of the IGF
signaling pathway in the development of Ewing Sarcoma
is evident through the ﬁnding that silencing of the EWS-
FLI1 oncoprotein showed upregulation and activation of
IGFBP genes [108]. Ewing Sarcoma cell lines are highly
sensitive to IGF1R inhibitors, especially in combination
with conventional chemotherapy [16, 109]. The IGF1R
antagonist, AMG 479, has shown promising results in the
treatment of ESFTs in a phase I clinical trial, indicating that
Ewing Sarcomas may be particularly sensitive to intervention
of the IGF1R signaling pathway [110, 111]. However, these
studies raise vital questions as to why striking responses are
seen in some, but not all, patients treated with these agents.
IGF1R and p53 drive distinctly opposing biological
outcomes, with a signiﬁcant level of molecular cross-talk
occurring between these two signaling pathways. Initial
studies suggested that p53 retorts the antiapoptotic sig-
naling of IGF1R through repression of IGF1R expression
[112]. Further antagonism of IGF1R activity by p53 was10 Sarcoma
Table 4 :I n v o l v e m e n to ft h eEWS gene in translocation-based malignancies.
Tumour type Fusion gene Translocation Reference
Ewing Sarcoma
EWS-FLI1 t(11;22)(q24;q12) [73]
EWS-ERG t(21;22)(q22;q12) [81]
EWS-ETV1 t(7;22)(p22;q12) [82]
EWS-ETV4 t(17;22)(q12;q12) [83]
EWS-FEV t(2;22)(q33;q12) [84]
Acute Leukemia EWS-CIZ1 t(12;22)(p13;q12) [85]
Angiomatoid Fibrous EWS-ATF1 t(12;22)(q13;q12) [86]
Histiocytoma EWS-CREB1 t(2;22)(q33;q12) [87]
Clear-cell Sarcoma EWS-ATF1 t(12;22)(q13;q12) [88]
EWS-CREB1 t(2;22)(q33;q12) [89]
Desmoplastic Small Round Cell Tumour EWS-WT1 t(11;22)(p13;q12) [90]
Extraskeletal Myxoid EWS-CHN1 t(9;22)(q22–31;q11-12) [91]
Chondrosarcoma EWS-NR4A3 t(9;22)(q22;q12) [92]
Myxoid Liposarcoma EWS-DDIT3 t(12;22)(q13;q12) [93]
demonstrated though the identiﬁcation of insulin-like
growth factor binding protein 3 (IGF-BP3) as a novel p53-
regulated target gene [113]. Induction of IGF-BP3 gene
expression by p53 enhanced secretion of an active form of
IGF-BP3 capable of inhibiting IGF1R mitogenic signalling.
Thus, the IGF1R signalling pathway is functionally antago-
nised by wild-type p53. Recent evidence has also shown that
IGF1R is degraded by MDM2 [114, 115]. Sequestration of
M D M 2i nt h en u c l e u sb yh i g hl e v e l so fm u t a n tp 5 3m a yb ea
possible explanation for the high levels of IGF1R observed in
some cancers [115].
Interestingly, pharmacological inhibition of IGF1R sig-
nalling reduces MDM2 translational synthesis, which in turn
stabilizes p53 [116]. IGF1R signalling therefore regulates
the p53 pathway. Hence, the overexpression of IGF1R and
frequent retention of a functional, wild-type p53 present an
opportunity of combined use of speciﬁc IGF1R inhibitors
with activators of the p53 pathway.
10.Pharmacological p53 ActivationAs
a Systemic Therapy for Ewing Sarcoma
Ewing Sarcomas provide a unique tumor type in which the
majority of cases retain the functionally intact p53 pathways
thatarekeptincheckbyeitherEWS-FLI1orthroughanother
unknownmechanism.Atpresent,thereisnoevidenceofper-
manent suppression of the p53 pathway by speciﬁc mutation
of critical components. Therefore, the most likely scenario
involves abrogation of p53 function via a reversible, post-
translational mechanism. This provides unique therapeutic
opportunities through intervention with small molecules
that directly stabilize and activate endogenous intracellular
p53. This concept was ﬁrst demonstrated using Nutlin-3a,
a small molecule antagonist of MDM2, which has shown
antitumour activity in vitro and in vivo through activation
of the p53 pathway in tumour cells that retain wild-type
p53[117].Nutlin-3aantagonizesthep53-MDM2interaction
by blocking the p53-binding pocket of MDM2 and as a
consequence there is a rapid stabilization and accumulation
of p53 protein levels [117]. Promising results from several
preclinical studies have clearly demonstrated the therapeutic
potentialofNutlin-3ainavarietyoftumourtypesexpressing
wild-type p53, including liposarcoma [118], rhabdomyosar-
coma [119], osteosarcoma [117], synovial sarcoma [120],
neuroblastoma [121], retinoblastoma [64], and leukemia
[122–124].
We have recently investigated the potential of a p53-
targeted therapeutic approach for the treatment of Ewing
Sarcoma using Nutlin-3a. Interestingly, exposure of Ewing
Sarcoma cell lines to Nutlin-3a resulted in a robust apoptotic
phenotype [125]. Nutlin-3a induced apoptosis required the
presence of a wild-type p53 and did not inﬂuence the growth
of ESFT cell lines expressing mutant p53. These ﬁndings
provide conﬁrmation of the functionality of downstream
p53 pathways in ESFTs retaining wild-type p53 and suggest
that p53 activators will provide a novel molecular-based
therapeutic for the majority of ESFTs.
Due to its aggressive nature and early systematic
spread, treatment of ESFT is highly challenging. Current
treatment protocols for ESFT patients involve multiagent
chemotherapy [15]. Prior to the introduction of combina-
tional chemotherapy, 5-year survival for patients diagnosed
with ESFT was less than 10% [126]. Since the introduc-
tion of intensive VACD-IE (vincristine, actinomycin D,
cyclophosphamide, doxorubicin, etoposide, and ifosfamide)
chemotherapy regimens, the current 5-year survival rates
for patients with localised disease are ranging from 60 to
70% [15, 127]. Nevertheless, Ewing Sarcoma still has the
lowest survival rates of any of the musculoskeletal tumours,
with minimal improvements to patient outcomes observed
over the last decade. Hence, there is an urgent need to
develop targeted therapeutic approaches to augment the
action of these cytotoxic agents. The integral role of p53
in the DNA damage response pathways stimulated by these
genotoxic agents suggests that p53 activators such as Nutlin-
3a may provide a novel approach to augment intensiveSarcoma 11
Table 5: Chemical structures and proposed mechanisms of small molecule p53 activators.
Compound Molecular formula MWT Mechanism
Stage in
clinical
testing
O
O
O
O
N
N
N Cl
Cl
NH
Nutlin-3a
C30H30Cl2N4O4 581.5
Binds to MDM2 and
inhibits p53-MDM2
interaction
Phase I
OH
HO
NH
NH
N
H
O
O
Cl
Cl
F
MI-219
C27H32Cl2FN3O4 552.5
Binds to MDM2 and
inhibits p53-MDM2
interaction
Phase I
OH HO
S
O
S
RITA
C14H12O3S2 292.4 Binds to p53 and inhibits
p53-MDM2 interaction Preclinical
H
H H
N
N
N N O
O S
Tenovin-6
C25H34N4O2S 454.6 SIRT1 and SIRT2
inhibition Preclinical
NH HN
N
N
N N
N N
N
O
O O
O
O
O
O
O
O O
NH HN
O
O
O O O
O
Actinomycin D
CH3
CH3
CH3
CH3
CH3
CH3 CH3
CH3
CH3
H3C
H3C
H3C
H3C
H3C
H3C
H3C
NH2
C62H86N12O16 1255.5 RPL11 and RPL5 release Clinically
approved
chemotherapies. Indeed, Nutlin-3a demonstrated synergistic
activity with numerous chemotherapies from the VACD-IE
protocol in Ewing Sarcoma [125] and in rhabdomyosarcoma
[119]. Such encouraging observations will require further
evaluation by the conduct of clinical trials using p53
activators as systemic therapies in combination with the
current chemotherapy regimens for the treatment of wild-
type p53 sarcomas.
The identiﬁcation of additional drugs that work on the
same principle as Nutlin-3a is an area of active research
within the p53 community. The majority of reported p53
activators (Table 5) have been shown to rapidly stabilize and12 Sarcoma
activate p53 protein levels through inhibition of the MDM2-
p53 interaction. One such example is the recently identiﬁed
MI-219, a highly selective MDM2 antagonist [128]. MI-
219 interacts with the p53 binding pocket of MDM2 with
ah i g h e ra ﬃnity and selectivity than Nutlin-3a and hence
attains a more potent stimulation of the p53 pathway.
MI-219 was observed to achieve p53-dependent antitumor
activity without causing visible signs of toxicity or gross
abnormalities in mice [128]. In addition, MI-219 exhibits
highly desirable pharmacokinetic properties and is currently
in early-phase clinical trials. Small molecule p53 activators
can also function through direct interaction with p53, as
demonstrated with RITA (Reactivation of p53 and induction
of tumour cell apoptosis) [129]. Preclinical studies show
that RITA can induce a nongenotoxic activation of p53
through inhibition of the MDM2-p53 interaction via direct
interaction with N-terminal domain of p53.
MDM2 antagonists have been demonstrated to elicit
their most potent eﬀects in cell lines where MDM2 is
ampliﬁed or overexpressed [118]. Since this genetic event
is not observed in all tumour types, small molecules that
activate p53 through alternative pathways have been devel-
oped. Lain and colleagues identiﬁed the Tenovins, a class
of p53 activators that enhance the acetylation of p53 [130].
The mechanism of action of Tenovin-1 and the water soluble
analog Tenovin-6 involve the direct inhibition of SIRT1 and
SIRT2, two members of the sirtuin family of class III histone
deacetylases responsible for the deacetylation of p53 [131–
133]. It is widely accepted that acetylation is an indispensible
modiﬁcation of p53 that occurs during speciﬁc activation
of the p53 pathway [134, 135]. Interestingly, Tenovin-6 was
shown to repress the growth of cancer cells using in vitro and
in vivo models through hyperacetylation of p53 [130]. These
studies imply that pharmacological inhibition of sitrins is an
eﬀective approach for p53 activation.
Although speciﬁc p53 activation in tumours is an
attractive therapeutic approach, these recently developed
small molecules are under investigation in preclinical or
early-phase clinical trials. In an attempt to accelerate the
implementation of p53 activators in the clinic, a study led
by Choong and colleagues screened a library of clinically
approved drugs and successfully identiﬁed actinomycin D as
a compound which mimics the action of Nutlin-3a when
administered at speciﬁc dosages [136]. Surprisingly, low
doses of actinomycin D induced speciﬁc activation of the
p53 pathway with cellular responses remarkably similar to
that of Nutlin-3a. These concentrations of actinomycin D
were also demonstrated to augment the cytotoxic actions of
chemotherapeutic drugs in cancer cells with wild-type p53
[136]. As actinomycin D is an FDA-approved drug, these
ﬁndings catalyze the immediate application of a p53-based
targeted therapeutic approach in the clinic.
High doses of actinomycin D are associated with inter-
calation into the DNA and subsequent double-strand DNA
breaks [137]. It is presently used in the clinic as a chemother-
apeutic agent and is a component of the highly successful
combination treatment for Wilm’s tumour. The inclusion of
actinomycin D in current multiagent chemotherapy regimes
for Ewing Sarcoma is variable amongst diﬀerent clinical
centers and is often dependent on the age of the patient.
Since the pharmacokinetic data available for actinomycin
Di sl i m i t e d[ 138, 139], comparison between the required
in vivo dosages of this drug with the low concentrations
used in vitro which elicit speciﬁc activation of p53 remains
a formidable challenge. Interestingly, Ewing Sarcoma cells
are highly sensitive to actinomycin D in vitro,w i t hp o t e n t
antitumour activity observed within the ranges described
as “low dose” speciﬁcally in Ewing Sarcoma cell line that
retains wild type p53 [125]. Further studies are warranted
to evaluate the potential of incorporation of low dose
actinomycin D with the current standard of care for the
treatment of patients with wild-type p53 ESFTs.
11. Conclusion
Ewing Sarcomas share the common genetic features includ-
ing the universal presence of the EWS-ETS translocation and
frequent retention of the wild-type p53 and its associated
functional downstream pathways. Targeted exploitation of
the p53 pathway holds great promise to enhance the
activity of current ESFT treatment regimes and improve
the currently poor survival rates associated with Ewing
Sarcoma. Recent identiﬁcation of the ﬁrst clinically approved
drug, actinomycin D, as a p53 activator has facilitated the
translation of these targeted therapies into current ESFT
treatment regimens. Low dose actinomycin D hold an
exciting potential as a directed molecular-based approach
to speciﬁcally activate wild-type p53 in ESFTs, and the
organization of clinical trials currently in progress to attest
the potential ofthis approach.Inaddition, complementation
of these studies with direct TP53 sequencing of ESFT
material would identify either patients with wild-type p53
t u m o u r sm o s tl i k e l yt ob e n e ﬁ tf r o mp 5 3 - b a s e dt h e r a p i e so r
the less frequent “high risk” population of ESFTs containing
point mutations in the TP53 gene.
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